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Abstract
Aims/hypothesis The aim of this study was to characterise islet autoantibody profiles and immune cell phenotypes in slow
progressors to type 1 diabetes.
Methods Immunological variables were compared across peripheral blood samples obtained from slow progressors to type 1
diabetes, individuals with newly diagnosed or long-standing type 1 diabetes, and healthy individuals. Polychromatic flow
cytometry was used to characterise the phenotypic attributes of B and T cells. Islet autoantigen-specific B cells were quantified
using an enzyme-linked immunospot (ELISpot) assay and islet autoantigen-specific CD8+ Tcells were quantified using peptide–
HLA class I tetramers. Radioimmunoassays were used to detect islet autoantibodies. Sera were assayed for various chemokines,
cytokines and soluble receptors via ELISAs.
Results Islet autoantibodies were lost over time in slow progressors. Various B cell subsets expressed higher levels of CD95 in
slow progressors, especially after polyclonal stimulation, compared with the corresponding B cell subsets in healthy donors
(p < 0.05). The phenotypic characteristics of CD4+ and CD8+ Tcells were similar in slow progressors and healthy donors. Lower
frequencies of CD4+ T cells with a central memory phenotype (CD27int, CD127+, CD95int) were observed in slow progressors
compared with healthy donors (mean percentage of total CD4+ T cells was 3.00% in slow progressors vs 4.67% in healthy
donors, p < 0.05). Autoreactive B cell responses to proinsulin were detected at higher frequencies in slow progressors compared
with healthy donors (median no. of spots was 0 in healthy donors vs 24.34 in slow progressors, p < 0.05) in an ELISpot assay.
Islet autoantigen-specific CD8+ T cell responses were largely absent in slow progressors and healthy donors. Serum levels of
DcR3, the decoy receptor for CD95L, were elevated in slow progressors compared with healthy donors (median was 1087 pg/ml
in slow progressors vs 651 pg/ml in healthy donors, p = 0.06).
Conclusions/interpretation In this study, we found that slow progression to type 1 diabetes was associated with a loss of islet
autoantibodies and a distinct B cell phenotype, consistent with enhanced apoptotic regulation of peripheral autoreactivity via
CD95. These phenotypic changes warrant further studies in larger cohorts to determine their functional implications.
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Abbreviations
BAFF B cell activating factor
BOX Bart’s Oxford Family Study
CXCR3 C-X-C motif chemokine receptor 3
DcR3 Decoy receptor 3
ELISpot Enzyme-linked immunospot
GADA GAD autoantibodies
IA-2 Islet antigen-2
IA-2A Islet antigen-2 autoantibodies
IAA Insulin autoantibodies
PBMC Peripheral blood mononuclear cell
PD-1 Programmed cell-death protein 1
SNAIL Slow or Non-progressive Autoimmunity to the
Islets of Langerhans
SPADE Spanning-tree Progression Analysis of Density-
normalized Events
ZnT8A Zinc transporter 8 autoantibodies
Introduction
The presence of autoantibodies specific for two or more islet
antigens is a reliable predictor of progression to type 1 diabetes.
Longitudinal studies of at-risk individuals have shown, however,
that up to 30% of people positive for multiple autoantibodies do
not progress to type 1 diabetes within 10 years [1]. Such
individuals were recruited to the Slow or Non-progressive
Autoimmunity to the Islets of Langerhans (SNAIL) study from
five other cohort studies, including the Bart’s Oxford Family
Study (BOX) [2]. All four major autoantibodies, specific for
GAD (GADA), islet antigen-2 (IA-2A), insulin (IAA) and zinc
transporter 8 (ZnT8A), were found in these slow progressors to
type 1 diabetes (hereafter referred to as ‘slow progressors’). The
frequency ofHLA class II risk alleles in this cohort was similar to
that observed in children diagnosed with type 1 diabetes over the
age of 10 years. Other factors may therefore be responsible for
non-progression, and the identification of protective mechanisms
could inform future preventive therapies.
People with type 1 diabetes display altered frequencies and
function of a number of lymphocyte subsets, as well as differ-
ent expression levels of surface markers; frequency and
suppressive ability of Tregs are reduced in type 1 diabetes
[3]. Expression of C-X-C motif chemokine receptor 3
(CXCR3) is reduced on CD3+ T cells in individuals with
long-standing type 1 diabetes [4–6]. Although beta cell-
autoreactive CD8+ T cells are found in healthy volunteers,
these CD8+ T cells from people with type 1 diabetes have a
more differentiated phenotype that includes TSCM [7].
Reported perturbations among B cell subsets in type 1 diabe-
tes include increased frequencies of transi t ional
(CD27−IgD+IgM−) B cells [8], increased frequencies of
marginal zone (CD19+CD21+CD23−) B cells and decreased
frequencies of follicular (CD19+CD21−CD23+) and regulato-
ry (CD1d+CD5+CD19+) B cells [9]. Furthermore, there are
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decreased frequencies of other putative regulatory
(CD24++CD38++) B cells [10] and decreased frequencies of
CD40+IL10+ B cells [11]. In addition, high-affinity insulin-
binding B cells are lost from the peripheral blood of people
with newly diagnosed type 1 diabetes, along with other
anergic B cells, and these return in people with long-
standing type 1 diabetes [12]. Some individuals with type 1
diabetes also exhibit reduced frequencies of circulating B cells
that express CD95 (FasR) and transmembrane activator and
CAML receptor (TACI) [13]. We have recently found that B
cells from people with long-standing diabetes display reduced
expression of CXCR3, CD95, B220 and CD24 [6].
The SNAIL study participants may also have biomarkers
determining which autoantibody-positive individuals are
protected from development of diabetes. In this study, we
characterised the immunological profiles of slow progressors
recruited to the BOX study (n = 10), people with newly diag-
nosed or long-standing type 1 diabetes (n = 18 in each group),
and healthy donors (n = 23). In addition, for the HLA class I-A2+
individuals, we also assessed the ability of the CD8+ T cells to
recognise autoantigenic peptides, presented byHLA-A2–peptide
tetramers (n = 5 for healthy donors, 7 for slow progressors, 9 for
newly diagnosed diabetes and 10 for long-standing diabetes).
Finally, we analysed serum cytokine and chemokine expression,
comparing slow progressors with healthy donors, and people
with newly diagnosed and long-standing type 1 diabetes.
Methods
Participants The BOX study is a longitudinal study examining
risk factors for type 1 diabetes in parents or siblings of
probands diagnosed under the age of 21 [14]. Between 1985
and 2012, islet autoantibodies were tested in at least one
sample from 5881 relatives who were free from diabetes at
the time of testing. Slow progressors were defined as people,
initially seropositive for at least two islet-specific autoanti-
bodies, who remained free from diabetes for at least 10 years.
Of 36 slow progressors identified in the BOX study,
confirmed asmultiple islet autoantibody positive using current
harmonised assays [2], 19 were not included in the current
analysis: 11 were excluded because they developed diabetes
more than 10 years after the initial serum sample (and no
follow-up serum sample was available after the 10 year point
before they had developed diabetes); seven were lost to
follow-up; and one had chronic lymphocytic leukaemia.
For this islet-specific autoantibody analysis, we examined
17 slow progressors with a first multiple islet autoantibody
sample available and a follow-up sample taken more than
10 years later (Fig. 1). Subsequently, a further three slow
progressors developed diabetes, one was lost to follow-up
and three declined further sampling. The remaining ten slow
progressors provided large-volume blood samples for the
immunology studies described here. The consort diagram is
illustrated in electronic supplementary material (ESM) Fig. 1.
We recruited sex-matched healthy donors of similar age,
seronegative for islet-specific autoantibodies, with no family
history of type 1 diabetes or other autoimmune conditions.
Adults with newly diagnosed or long-standing type 1
diabetes were also recruited, to provide context for the simi-
larities or differences observed between healthy donors and
slow progressors. Type 1 diabetes was diagnosed according
ADA criteria [15] and insulin treatment was commencedwith-
in 1 month of diagnosis. Time from diagnosis was categorised
as <1 year for newly diagnosed individuals and >3 years for
individuals with long-standing diabetes. Cohort details are
summarised in ESM Table 1.
Ethics The BOX study was approved by the South Central–
Oxford C National Research Ethics Committee. Study of
progressors and control individuals was approved by the
South East Wales Research Ethics Committee and conducted
in accordance with the principles of Good Clinical Practice
established by the International Council for Harmonization/
WHO. All participants provided written informed consent
prior to enrolment, as mandated by the Declaration of
Helsinki.
Islet-specific autoantibodiesGADA, IA-2A, IAA and ZnT8A
were measured using fully validated radioimmunoassays [16].
The higher value from two distinct assays, one for the R325
variant and one for the W325 variant, was reported for
ZnT8A. Titres of IAA and ZnT8A, measured in duplicate in
5 μl and 2 μl of serum respectively, were expressed in units
derived from in-house standard curves. Titres of GADA and
IA-2Awere expressed in digestive and kidney (DK) units/ml
derived from a standard curve developed for the NIDDK-
sponsored Islet Autoantibody Harmonization Program [17].
HLA class II genotyping Genomic DNA was extracted from
whole-blood samples collected in EDTA. HLA class II DRB1
alleles were resolved using polymerase chain reactions with
sequence-specific primers [18].
Blood samples Peripheral blood mononuclear cells (PBMCs)
were isolated from heparinised samples of whole blood via
density gradient centrifugation over Lymphoprep (Stem Cell
Technologies, Cambridge, UK). Aliquots of 5 × 106 to 20 ×
106 PBMCs/ml per vial were stored in liquid nitrogen after
cooling overnight to −80°C at a controlled rate of −1°C/min in
a Cryostor CS10 (Sigma-Aldrich, St Louis, MO, USA).
Tetramers Fluorochrome-labelled peptide-HLA-A2 tetramers
were assembled from monomers from NIH Tetramer Core
Facility (Atlanta, GA, USA) and streptavidin Qdots (Thermo
Fisher Scientific, Waltham, MA, USA). Tetramer staining was
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performed as described previously [19]. Briefly, thawed
PBMCs were treated with 50 nmol/l dasatinib for 15 min at
37°C, then pelleted and resuspended in tetramer Qdot master
mix for 15 min at 37°C (details in ESM Table 2). Cells were
incubated with LIVE/DEAD Fixable Aqua (Thermo Fisher
Scientific) for 10 min at room temperature and stained for
30 min at 4°C with titrated concentrations of the following
antibodies: anti-CD8–AF700 (clone RPA-T8) (BD
Biosciences, San Jose, CA, USA); anti-CD4–FITC (clone
OKT4); anti-CD14–FITC (clone 61D3); anti-CD16–FITC
(clone eBioCB16); anti-CD20–FITC (clone 2H7); and anti-
CD40–FITC (clone 5C3) (dump channel; eBioscience, San
Diego, CA, USA). Data were acquired using a modified
FACSAria II flow cytometer (BD Biosciences). All flow
cytometry data were analysed with FlowJo software version
10 (Tree Star, Ashland, OR, USA).
T cell panel Thawed PBMCs were blocked with TruStain
(BioLegend, San Diego, CA, USA) for 5 min at room temper-
ature, incubated with LIVE/DEAD Fixable Aqua (Thermo
Fisher Scientific) for 10 min at room temperature and stained
for 30 min at 4°C with titrated concentrations of the following
antibodies: (1) anti-CD3–APC/Fire750 (clone SK7), anti-
CD8a–BV711 (clone RPA-T8), anti-CD57–PE-Cy7 (clone
HNK-1), anti-CD95–PE-Cy5 (clone DX2) and anti-PD-1–
BV421 (clone EH12.2H7) (BioLegend); (2) anti-CD45RA–
ECD (clone 2H4LDH11LDB9) and anti-CD127–PE (clone
R34.34) (Beckman Coulter, Brea, CA, USA); (3) anti-
CD14–V500 (clone MSE2) and anti-CD19–V500 (clone
HIB19) (BD Biosciences); (4) anti-CD4–PE-Cy5.5 (clone
S3.5) and anti-CD27–Qdot 605 (clone CLB-27/1) (Thermo
Fisher Scientific); and (5) anti-CXCR3–FITC (clone 49801)
(R&D Systems, Minneapolis, MN, USA). Cells were then
Fig. 1 Loss of autoantibodies in some slow progressors over time. Islet
autoantibody titres were measured in follow-up samples obtained from
slow progressors (n = 17) at least 10 years after initial testing (index) as
part of the BOX study. Follow-up samples were acquired at the time of
sampling for immune cell analysis (n = 10), before/at diagnosis (n = 3), or
as recently as possible (n = 4). (a–d) Only titres for individuals positive
for a specific autoantibody are shown: (a) GADA (n = 16); (b) IA-2A
(n = 10); (c) IAA (n = 6); (d) ZnT8A (n = 12). Dotted lines indicate the
threshold for seropositive islet autoantibody titres: GADA ≥33 DK units/
ml; IA-2A ≥1.4 DK units/ml; IAA ≥0.2 units; ZnT8A ≥1.8 units. GADA
and IA-2A titres are expressed in DK units/ml derived from a standard
curve developed for the NIDDK-sponsored Islet Autoantibody
Harmonization Program. IAA and ZnT8A titres are expressed in units
derived from in-house standard curves, measured in duplicate in 5 μl and
2 μl of serum respectively. *p < 0.05 and **p < 0.01 for follow-up vs
index (determined using the Wilcoxon matched pairs test). (e)
Proportion of individuals with 0, 1, 2 or 3 autoantibodies (GADA, IA-
2A, IAA and/or ZnT8A); p = 0.007 determined using Fisher’s exact test
comparing groups of ≥2 and <2 autoantibodies for index vs follow-up
samples
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washed in PBS containing 0.5% wt/vol. BSA and 2 mmol/l
EDTA, fixed with 1% wt/vol. paraformaldehyde and acquired
using a modified FACSAria II flow cytometer (BD
Biosciences).
B cell panel Thawed PBMCs were blocked with TruStain
(BioLegend) for 5 min at room temperature, incubated with
LIVE/DEAD Fixable Aqua (Thermo Fisher Scientific) for
10 min at room temperature and stained for 30 min at 4°C
with titrated concentrations of the following antibodies: (1)
anti-CD19–PE-Cy7 (clone SJ25C1) and anti-CD24–APC-
eFluor780 (clone SN3) (eBioscience); (2) anti-CD3–BV711
(clone OKT3), anti-CD45R/B220–BV421 (clone RA3-6B2)
and anti-IgD–AF488 (clone IA6-2) (BioLegend); (3) anti-
CD27–Qdot 605 (clone CLB-27/1) (Thermo Fisher
Scientific); (4) anti-CD21–PE-Cy5 (clone B-ly4), anti-
CD38–PE-CF594 (clone HIT2) and anti-CXCR3–PE (clone
IC6/CXCR3) (BD Biosciences); and (5) anti-CD95–APC
(clone DX2) (Miltenyi Biotec, Bergisch Gladbach,
Germany). Cells were then washed in PBS containing 0.5%
wt/vol. BSA and 2 mmol/l EDTA, fixed with 1%wt/vol. para-
formaldehyde, and acquired using a modified FACSAria II
flow cytometer (BD Biosciences) or an LSR Fortessa (for
stimulated B cells).
B cell stimulation Freshly isolated PBMCs were cultured with
0.5 μmol/l CpG oligodeoxynucleotide 2006 (Eurofin
Genomics, Ebersberg, Germany), 0.5 μg/ml protein-A soluble
from Staphylococcus aureus Cowan strain (Sigma-Aldrich)
and 1 μg/ml pokeweed mitogen (Sigma-Aldrich) in 10%
heat-inactivated AB serum/RPMI (stimulated) or with 10%
heat-inactivated AB serum/RPMI alone (unstimulated) for
5 days at 37°C.
B cell enzyme-linked immunospot assay For the enzyme-
linked immunospot (ELISpot) assay, multiScreen-IP filter
plates (Merck Millipore, Burlington, MA, USA) were pre-
wetted with 70% molecular grade ethanol (Sigma-Aldrich),
washed and coated with PBS, 0.5 μg/ml goat anti-human
IgG (Newmarket Scientific, Newmarket, UK), 0.8 or
1.6 μg/ml GAD (RSR, Dallas, TX, USA), 0.8 or 1.6 μg/ml
islet antigen-2 (IA-2) (RSR), or 10 or 50 μg/ml proinsulin
(Biomm, Nova Lima, Brazil) overnight at 4°C. Plates were
washed and blocked with 10% heat-inactivated FBS/RPMI
overnight at 4°C. Stimulated cells were washed in 10% heat-
inactivated FBS/RPMI, resuspended at 5 × 105 cells/ml (for
the IgG positive control) or 4 × 106 cells/ml (for all other
conditions), and plated at 100 μl/well (n ≥ 6 wells per condi-
tion). Plates were incubated for 5 h at 37°C, washed in 0.05%
Tween 20/PBS and coated with 0.5 μg/ml goat anti-human
IgG Fc biotin in 5% heat-inactivated FBS/PBS overnight at
4°C. Antibody secretion was revealed using ExtrAvidin
(Sigma-Aldrich) followed by BCIP/NBT substrate (Sigma-
Aldrich). Plates were washed and dried overnight and spots
were counted using a BIO-SYS Bioreader 4000 (BioSys,
Miami, FL, USA). The PBS background was subtracted from
all counts (mean±SD background 142 ± 75, range 30.5–245,
not significantly different between healthy donors and slow
progressors).
Spanning-tree progression analysis of density-normalised
events Live T cells were identified in serial gates as singlets,
lymphocytes, LIVE/DEAD Fixable Aqua−, CD19−, CD3+
events and gated as CD4+, CD8+, CD4/CD8 double-positive,
or CD4/CD8 double-negative cells using FlowJo.
Compensated flow cytometry files were exported for
Spanning-tree Progression Analysis of Density-normalized
Events (SPADE) using fixed settings (K-means algorithm,
100 clusters, Arcsinh transformation with cofactor 150) in
SPADE software version 3.0 [6, 20, 21]. Expression of cell
surface markers (CD3, CD4, CD8, CD27, CD57, CD95,
CD45RA, CD127, CXCR3 and programmed cell-death
protein 1 [PD-1]) was assessed. Live B cells were identified
in serial gates as singlets, lymphocytes, LIVE/DEAD Fixable
Aqua−, CD3−, CD19+ events using FlowJo. Data were proc-
essed as above with the same settings in SPADE. Expression
of cell surface markers (B220, CD19, CD21, CD24, CD27,
CD38, CD95, CXCR3 and IgD) was assessed. Auto-
partitioning was used to divide the resulting trees into eight
areas. Median expression of each marker was calculated for
each donor in each node.
Serum chemokines, cytokines and soluble receptors Serum
samples were analysed using the Meso Scale Discovery U-
PLEX platform to quantify CXCL10, CXCL11, IL-4, IL-6,
IL-10 and IFN-γ (MSD, Rockville, MD, USA) or DuoSet
ELISA Kits to quantify B cell activating factor (BAFF),
CD95L (FasL), CXCL9, Decoy receptor 3 (DcR3) and
TGF-β (R&D Systems).
Statistics Differences in mean values between two groups
were compared using an unpaired Student’s t test (if the data
were normally distributed) or theMann–WhitneyU test (if the
data were not normally distributed). Immune cell variables
were compared primarily between slow progressors and
healthy donors. Newly diagnosed and long-standing type 1
diabetes samples were included to add context but were not
included in statistical analysis due to small sample sizes and
lack of age matching between newly diagnosed individuals
and slow progressors. Therefore, no statistical comparisons
were made between people with type 1 diabetes and either
healthy donors or slow progressors. The exception to this
was the peptide-HLA-A2 tetramer study, where people with
type 1 diabetes were used as a positive control to validate the
assay and results were compared between people with type 1
diabetes and healthy donors using a Mann–Whitney U test.
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Individual autoantibody titres at different time-points were
compared using the Wilcoxon matched pairs test. The number
of autoantibodies with elevated titres was compared across
time-points using Fisher’s exact test. All statistical tests were
performed using Prism software version 6 (GraphPad, San
Diego, CA, USA).
Results
Islet autoantibody profiles show that some slow progressors
lose autoantibodies over time Slow progressors were initially
seropositive for at least two islet autoantibodies, the titres of
which decreased over time in most people (GADA n = 16, p =
0.029; IA-2A n = 10, p = 0.014; IAA n = 6, p = 0.094; ZnT8A
n = 12, p = 0.002) (Fig. 1a–d). Of the 17 slow progressors
included in longitudinal islet autoantibody analysis in this
study, four (24%) did not lose positivity for any islet autoan-
tibody although in general the titre decreased over time. Of the
remainder, we observed and confirmed loss of IAA four times,
ZnT8A twice, IA-2A once and GADA once. However, anti-
body loss was not confirmed in four individuals with ZnT8A
and one individual with GADA because these occurred in the
most recent sample. Overall, multiple antibody positivity
decreased (p = 0.007) (Fig. 1e). In the cohort of slow
progressors analysed for immune cell variables (n = 10), the
number of autoantibodies with titres considered seropositive
was either reduced from three to two (n = 1) or from two to
one (n = 3) in the test samples (the latter indicated by red
squares in subsequent figures), or remained unchanged rela-
tive to the index sample (n = 6) (ESM Table 1).
Slow progressors do not show islet autoantigen-specific CD8+
T cell responses HLA-A2+ participants were tested for CD8+
T cell responses to known islet autoantigens using peptide–
HLA-A2 tetramers (ESM Table 2). Minimal islet autoantigen-
specific CD8+ T cell responses were observed in slow
progressors and healthy donors (Fig. 2a–f and ESM Fig. 2).
In contrast, individuals with newly diagnosed type 1 diabetes
harboured significantly higher frequencies of CD8+ T cells
specific for epitopes derived from GAD (p < 0.05), proinsulin
(p < 0.05), islet-specific glucose-6-phosphatase catalytic
subunit-related protein (p < 0.05) and insulin (p < 0.05)
compared with healthy donors (Fig. 2b–e), and individuals
with long-standing type 1 diabetes harboured significantly
higher frequencies of CD8+ T cells specific for the epitopes
derived from GAD (p < 0.05) and insulin (p < 0.05) compared
with healthy donors (Fig. 2b,e).
T cells from slow progressors show decreased CD95 expres-
sion and a decreased percentage of central memory T cells
Expression of the following cell surface markers was assessed
using flow cytometry: CD3, CD4, CD8, CD27, CD57, CD95,
CD45RA, CD127, CXCR3 and PD-1. Viable CD3+ cells were
gated as CD4+, CD8+, double-positive or double-negative
events and exported for multivariate analysis in SPADE
(Fig. 3a–d). The resulting SPADE tree was auto-partitioned
into eight annotated areas and the cells that were in each area
Fig. 2 Islet autoantigen-specific CD8+ T cell responses are not found in
slow progressors. HLA-A2+ participants were tested for CD8+ T cell
responses to known islet autoantigens using peptide–HLA-A2 tetramers
(ESM Table 2). Background staining was determined using a non-inter-
facing peptide–HLA-A2 tetramer. Results are shown as background-
subtracted frequencies among CD8+ T cells. Tetramer responses are
shown to: (a) islet amyloid polypeptide (KLQVFLIVL); (b) GAD
(VMNILLQYVV); (c) proinsulin (ALWGPDPAAA); (d) islet-specific
glucose-6-phosphatase catalytic subunit-related protein (VLFGLGFAI);
(e) insulin (HLVEALYLV); (f) IA-2 (MVWESGCTV). Red squares
denote slow progressors who tested seropositive for a single islet
autoantibody at the time of immune cell analysis. Horizontal lines indi-
cate median values. Results for people with newly diagnosed and long-
standing type 1 diabetes are shown in grey to add context and to represent
a positive control in the assay but were not included in the statistical
analysis shown on the graph due to small sample sizes and lack of age
matching between newly diagnosed and slow-progressing donors. HD,
healthy donors; IA-2, insulin antigen-2; IAPP, islet amyloid polypeptide;
IGRP, islet-specific glucose-6-phosphatase catalytic subunit-related
protein; INS, insulin; LS, long-standing type 1 diabetes; ND, newly diag-
nosed type 1 diabetes; PI, proinsulin; SP, slow progressors
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were identified based on the expression of CD27, IgD and
additional markers. Slow progressors exhibited decreased
expression of CD95 among CD4+ T cells with a transitional
memory phenotype (area 7; CD27+ CD45RA−CD127+PD-
1++) compared with healthy donors (p < 0.05) (Fig. 3c).
Lower frequencies of CD4+ T cells with a central memory
phenotype (area 8; CD27intCD45RA−CD127+CD95int) were
also present in slow progressors compared with healthy
donors (mean percentage of total CD4+ T cells was 4.67% in
healthy donors vs 3.00% in slow progressors, p < 0.05) (Fig.
3d). These differences were not observed in individuals with
newly diagnosed or long-standing type 1 diabetes. Moreover,
higher frequencies of CD4+ T cells with a central memory
phenotype (CD27intCD127+CD95int) were detected in indi-
viduals with newly diagnosed type 1 diabetes (mean percent-
age of total CD4+ Tcells was 7.78%, p < 0.05) compared with
healthy donors (Fig. 3d). Representative flow cytometric plots
of analogous populations of cells, manually gated in FlowJo
are shown in ESM Fig. 3.
B cells from slow progressors show increased expression of
CD95 Expression of the following cell surface markers was
assessed using flow cytometry: B220, CD19, CD21, CD24,
CD27, CD38, CD95, CXCR3 and IgD. Viable CD3−CD19+
cells were gated and exported for multivariate analysis in
SPADE (Fig. 4a–c). First, we analysed the phenotype of the
B cells from uncultured PBMCs. All samples were thawed
and analysed on the same day using a panel of B cell pheno-
typing antibodies and SPADE. When compared with healthy
donors, the long-standing and newly diagnosed diabetes
cohorts had a number of phenotypic differences in the B cell
compartment. These included a decrease in CXCR3 expres-
sion, as we previously reported [6]. No such changes were
observed in the corresponding B cell subsets in slow
progressors. However, slow progressors exhibited increased
expression of CD95 among B cells with a switched memory
phenotype (CD27+, IgD−) compared with healthy donors
(p < 0.05), in contrast to individuals with newly diagnosed
or long-standing type 1 diabetes (Fig. 4c). Representative flow
cytometric plots of analogous populations of cells manually
gated in FlowJo are shown in ESM Fig. 4.
To extend these findings, we conducted parallel experi-
ments with stimulated B cells from slow progressors (n = 6),
individuals with newly diagnosed type 1 diabetes (n = 6) and
Fig. 3 Phenotypic characteristics of T cells in slow progressors indicate
decreased CD95 expression and a decreased percentage of central memo-
ry T cells. Expression of the indicated markers was assessed using flow
cytometry. (a) SPADE image of pooled CD4+ T cells from all partici-
pants, auto-partitioned into eight annotated areas with node size scaled to
the log number of cells in each node, showing median CD95 expression
as a heatmap. Based on the expression of CD27 and CD45RA, the cells in
the different areas were designated as follows: area 1, naive
(CD27+CD45RA+); area 2, effector (CD27−CD45RAint); area 3, effector
memory (CD27−CD45RA−); areas 4–8, memory (CD27int/+CD45RA−).
(b) SPADE boxplots showing marker distribution in each area or in all
areas for the pooled CD4+ Tcell samples depicted in (a). Central red lines
indicate median values and the ends of blue boxes indicate interquartile
ranges. The dashed horizontal line at the bottom indicates the ‘All’
category. (c) CD95 expression (transformed values) in CD4+ T cell area
7 for each participant. (d) Percentage of CD4+ T cells in CD4+ T cell area
8 for each participant. In (c) and (d), horizontal lines indicate mean values
and red squares denote slow progressors who tested seropositive for a
single islet autoantibody at the time of immune cell analysis. *p < 0.05 for
slow progressors vs healthy donors (determined using an unpaired
Student’s t test). Results for people with newly diagnosed and long-stand-
ing type 1 diabetes are shown in grey to add context but were not included
in statistical analysis due to small sample sizes and lack of age matching
between newly diagnosed and slow-progressing individuals. AU, arbi-
trary unit; HD, healthy donors; LS, long-standing type 1 diabetes; MFI,
median fluorescence intensity; ND, newly diagnosed type 1 diabetes; SP,
slow progressors
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healthy donors (n = 14) (Fig. 5a–h), prepared from freshly
isolated PBMCs. Slow progressors exhibited increased
expression of CD95 among various B cell subsets when
compared with healthy donors: area 1, switched memory
(CD27+IgD−); area 2, memory (CD27intIgDint); area 3,
switched memory (CD27intIgD−); area 5, switched
(CD27−IgD−); area 6, naive (CD27−IgD+) and area 7,
switched memory (CD27++IgD−); p < 0.05). Cells from indi-
viduals with newly diagnosed type 1 diabetes showed no such
changes (Fig. 5c–h and ESM Fig. 5).
Slow progressors show increased B cell responses to proinsu-
lin but not to GAD or insulin antigen-2Antibody-producing B
cells specific for the islet autoantigens GAD, IA-2 and proin-
sulin were quantified using an ELISpot assay [22]. No signif-
icant differences were observed between slow progressors and
healthy donors in response to stimulation with GAD or IA-2
(Fig. 6a,b). In contrast, slow progressors displayed higher
frequencies of antibody-producing B cells in response to
stimulation with proinsulin at 50 μg/ml (but not at
10 μg/ml), when compared with healthy donors (median
number of spots was 24.34 in slow progressors vs 0 in healthy
donors, p < 0.05) (Fig. 6c).
Serum chemokines, cytokines and soluble receptors No
significant differences in serum levels of BAFF, CD95,
CXCL9, CXCL10, CXCL11, IFN-γ, IL-4, IL-6, IL-10 or
TGF-β were detected between slow progressors and healthy
donors (data not shown). There was a non-statistically significant
increase in soluble DcR3, the decoy receptor for CD95L (median
serum concentration was 1087 pg/ml in slow progressors vs
651 pg/ml in healthy donors, p = 0.06) (ESM Fig. 6).
Discussion
In this study, we conducted an extensive immunological anal-
ysis of slow progressors, individuals with newly diagnosed or
Fig. 4 Phenotypic characterisation of unstimulated B cells in slow
progressors demonstrate increased expression of CD95 among B cells
with a switched memory phenotype. Expression of the indicated markers
in unstimulated samples was assessed using flow cytometry. (a) SPADE
image of pooled B cells from all participants, auto-partitioned into eight
annotated areas with node size scaled to the log number of cells in each
node, showing median CD95 expression as a heatmap. Based on the
expression of CD27 and IgD, the cells in the different areas were desig-
nated as follows: areas 1, 2 and 5, switched memory (CD27+IgD−); area
3, unswitched (CD27intIgD+); areas 4 and 7, naive (CD27−IgD+); area 6,
transitional (CD27intIgDint); area 8, naive/switched (CD27−IgDint). (b)
SPADE boxplots showing marker distribution in each area or in all areas
for the pooled samples depicted in (a). Central red lines indicate median
values and the ends of blue boxes indicate interquartile ranges. The
dashed horizontal line at the bottom indicates the ‘All’ category. (c)
CD95 expression (transformed values) in area 5 for each participant.
Horizontal lines indicate mean values and red squares denote slow
progressors who tested seropositive for a single islet autoantibody at the
time of immune cell analysis. *p < 0.05 for slow progressors vs healthy
donors (determined using an unpaired Student’s t test). Results for people
with newly diagnosed and long-standing type 1 diabetes are shown in
grey to add context but were not included in statistical analysis due to
small sample sizes and lack of age matching between newly diagnosed
and slow-progressing individuals. AU, arbitrary unit; HD, healthy
donors; LS, long-standing type 1 diabetes; MFI, median fluorescence
intensity; ND, newly diagnosed type 1 diabetes; SP, slow progressors
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long-standing type 1 diabetes, and healthy donors. Islet auto-
antibodies were lost over time in slow progressors. Moreover,
various B cell subsets expressed higher levels of CD95 in slow
progressors, especially after polyclonal stimulation, compared
with the corresponding B cell subsets in healthy donors. These
results suggested that autoreactive B cells may be more prone
to activation-induced apoptosis and clonal deletion in individ-
uals who are slow progressors, relative to those with newly
diagnosed or long-standing type 1 diabetes and healthy
donors.
Islet autoantigen-specific CD8+ T cell responses were
largely absent in slow progressors and healthy donors. The
phenotypic characteristics of CD4+ and CD8+ T cells were
also similar in slow progressors and healthy donors. Slow
progressors, however, exhibited decreased expression of
CD95 among CD4+ Tcells with a transitional memory pheno-
type (CD27+CD127+PD-1++), in contrast to most B cell
subsets. In addition, lower frequencies of CD4+ T cells with
a central memory phenotype (CD27intCD127+CD95int) were
present in slow progressors compared with healthy donors,
Fig. 5 Phenotypic characteristics of stimulated B cells in slow
progressors show increased CD95 expression compared with cells from
healthy donors. Expression of the indicated markers in stimulated
samples was assessed using flow cytometry. (a) SPADE image of pooled
B cells from all participants, auto-partitioned into eight annotated areas
with node size scaled to the log number of cells in each node, showing
median CD95 expression as a heatmap. Based on the expression of CD27
and IgD, the cells in the different areas were designated as follows: area 1,
switched memory (CD27+IgD−); area 2, memory (CD27intIgDint); area 3,
switched memory (CD27intIgD−); areas 4 and 5, switched (CD27−IgD−);
area 6, naive (CD27−IgD+); areas 7 and 8, switched memory
(CD27++IgD−). (b) SPADE boxplots of marker distribution in each area
or in all areas for the pooled samples depicted in (a). Central red lines
indicate median values and the ends of blue boxes indicate interquartile
ranges. The dashed horizontal line at the bottom indicates the ‘All’ cate-
gory. (c–h) CD95 expression (transformed values) in areas 1 (c), 2 (d), 3
(e), 5 (f), 6 (g) and 7 (h) for each participant. In (c–h), horizontal lines
indicate mean values and red squares denote slow progressors who tested
seropositive for a single islet autoantibody at the time of immune cell
analysis. *p < 0.05 and **p < 0.01 for slow progressors vs healthy donors
(determined using an unpaired Student’s t test). Results for people with
newly diagnosed type 1 diabetes are shown in grey to add context but
were not included in statistical analysis due to small sample sizes and lack
of age matching between newly diagnosed and slow-progressing individ-
uals. AU, arbitrary unit; HD, healthy donors; MFI, median fluorescence
intensity; ND, newly diagnosed type 1 diabetes; SP, slow progressors
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whereas higher frequencies of CD4+ T cells with a central
memory phenotype (CD27intCD127+CD95int) were detected
in people with newly diagnosed type 1 diabetes compared
with healthy donors, consistent with an earlier report [23]. It
is particularly intriguing that we detected low expression
levels of CD95 among memory CD4+ T cells, because
CD95 is known to promote apoptosis, which is required for
the elimination of autoreactive T cells that escape thymic
selection [24]. Previous reports have indicated that antigen-
specific CD4+ T cells may be found in the peripheral blood of
both healthy people and those with type 1 diabetes. The
antigen-specific cells in individuals with type 1 diabetes
expressed increased CXCR3 and decreased CCR7, indicating
differentiation to Th1-like effector cells [25]. Further work
will be required to examine the abundance and function of
antigen-specific CD4+ T cells in slow progressors.
We, and others, have found previously that CD95 is expressed
at relatively low levels on various B cell subsets in individuals
with type 1 diabetes [6, 13]. We found the opposite in slow
progressors. In individuals with systemic lupus erythematosus,
B cells in general express relatively high levels of CD95,whereas
autoreactive B cells in particular express relatively low levels of
CD95 [26]. Moreover, disease flares have been associated with
high frequencies of activated memory B cells, defined by the
expression of CD95 [26, 27]. Serum levels of DcR3, the decoy
receptor for CD95L, increased from a median of 651 pg/ml in
healthy donors to 1087 pg/ml in slow progressors (p = 0.06).
Therefore, the changes in expression of CD95 could also suggest
that there is increased activity of autoreactive B cells (unsurpris-
ing as the BOX participants are defined by the production of
autoantibodies).
We reported previously that while B cells from healthy indi-
viduals can respond to pancreatic antigens, including GAD and
IA2 when measured using an ELISpot assay, the B cells from
people with type 1 diabetes have a significantly increased
response [22]. Here we demonstrate that slow progressors do
not respond significantly more than healthy donors to either
GAD or IA2 but have significantly more spot-forming cells in
response to proinsulin. The lack of increased response to GAD
and IA2was interesting, given that many of the slow progressors
were positive for GAD autoantibodies in particular. In addition,
the polyclonal pre-stimulation induces memory B cells to differ-
entiate into antibody secreting cells [28] and would be expected
to overcome any anergy present in autoreactive B cells. Thus, we
infer that GAD- and IA2-reactive B cells are not more abundant
in the peripheral blood of the slow progressors compared with
healthy donors and suggest that the presence of autoantibodies in
the serum may be due to lower thresholds of B cell stimulation
for antibody production in the slow progressors. We also manu-
ally gated for CD24+++CD38++ ‘Bregs’ and found no difference
between the healthy donors and slow progressors (data not
shown). No direct comparison was made with individuals newly
diagnosed with type 1 diabetes due to the inability to age-match
slow progressors and newly diagnosed individuals, the latter
developing diabetes at a younger age.
One limitation of this study was the lack of a direct compar-
ator group, namely at-risk individuals who subsequently
progressed to type 1 diabetes. Moreover, immune cell vari-
ables were measured after some islet autoantibodies had
already been lost, potentially impacting the detection of
autoreactive B cell responses to GAD and IA-2. It would be
informative to study immune profiles in slow progressors
before and after islet autoantibody loss. In the small cohort
that we studied, we did not observe differences when compar-
ing the slow progressors who were only positive for a single
autoantibody at the time of sampling (indicated in red symbols
throughout the figures) and those who retained multiple auto-
antibody positivity; this would require repetition with more
slow progressors in order for firm conclusions to be drawn.
It is also possible that we selected for a particular subgroup of
Fig. 6 Islet autoantigen-specific B cell responses in slow progressors,
measured by ELISpot, are increased to proinsulin but not GAD or IA-2.
B cell responses to the indicated islet autoantigens were quantified using
an ELISpot assay to detect secreted IgG. Background responses were
determined in the absence of islet autoantigens. Results are shown as
the number of background-subtracted spots per 4 × 105 input PBMCs.
Counts were averaged over at least six wells for each condition.
ELISpot counts are shown for: (a) GAD at 0.8 μg/ml and 1.6 μg/ml;
(b) IA-2 at 0.8 μg/ml and 1.6 μg/ml; (c) proinsulin at 10 μg/ml and 50
μg/ml. Horizontal lines indicate median values. Red squares denote slow
progressors who tested seropositive for a single islet autoantibody at the
time of immune cell analysis. *p < 0.05 for slow progressors vs healthy
donors (determined using the Mann–Whitney U test). Bgd, background;
HD, healthy donors; SP, slow progressors
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at-risk individuals, defined by the presence of islet autoanti-
bodies, while another subgroupmay havemore autoreactive T
cells. Additional studies are therefore required to confirm the
findings reported here. Our data nonetheless reveal a mecha-
nistically coherent pattern of immunological traits in slow
progressors, suggesting a greater propensity for apoptotic
regulation of peripheral autoimmunity compared with healthy
individuals.
We are aware that the number of suitable BOX participants
that we used here is small and we aim to validate and expand
upon the results described here by studying slow progressors
from other collections in the SNAIL project.
In summary, B and Tcells from slow progressors were very
similar to those from healthy individuals. Crucially, CD8+ T
cell response to diabetogenic peptides were similarly low in
slow progressors and healthy individuals and we did not
observe an expansion of GAD or IA-2 antibody-producing
B cells in the peripheral blood. However, changes in CD95
on B cells in slow progressors suggested the possibility of
increased susceptibility of B cells to apoptosis. In future stud-
ies, we will aim to increase cohort sizes in order to address the
functional roles of the phenotypic changes, and to identify
markers predictive of protection from disease.
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